Clinical Trials Directory

Trials / Unknown

UnknownNCT01271140

High Dose Insulin Therapy to Improve Liver Function

High Dose Insulin Therapy to Improve Liver Function in Patients With HCV Liver Cirrhosis

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
5 (estimated)
Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Insulin resistance is one of the key factors in defining a progressive course of chronic Hepatitis C virus (HCV) infection and hepatic fibrosis. Multiple trials have targeted insulin resistance as an adjuvant way to manage hepatitis C liver disease with promising results. Long term therapy using high dose insulin was shown to significantly reduce insulin resistance in obese patients. In cardiac and critically ill patients, long term insulin was shown to produce better outcomes mainly by reducing the overt inflammatory response. Furthermore, initial results of ongoing trials are revealing more benefits of insulin therapy. Using the (hyperinsulinimic normoglycemic clamp) for eight hours on patients undergoing major liver resection was able to maximize their liver function post-operatively. This trial also demonstrated inhibition of the inflammatory response, improvement in liver glycogen, inhibition of apoptosis and stimulation of liver regeneration. Putting in mind the potential ability of the liver to regenerate and regain better function. The anti-inflammatory properties of insulin therapy along with its ability to reduce insulin resistance over time has led us to see the potential benefits of using insulin therapy on patients with chronic hepatitis C virus liver cirrhosis. Insulin will target the pathophysiology of the disease at a cellular and a molecular level. The investigators theorize that long-term high insulin therapy would be able to promote better liver function and slow down fibrosis and injury in this population of patients.

Conditions

Interventions

TypeNameDescription
DRUGInsulinIntravenous insulin clamp at a rate of 2 mlu/kg/hr. In adition a titrating dose of 20% dextrose aiming to a blood glucose level of 4 - 5.5 mmol/l.

Timeline

Start date
2011-01-01
Primary completion
2013-12-01
Completion
2014-06-01
First posted
2011-01-06
Last updated
2013-11-13

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT01271140. Inclusion in this directory is not an endorsement.